By Fineline Cube China-based Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) has announced that it has received approval from the US FDA to conduct a clinical study for its jinnamab in adult-onset still disease (AOSD).
Understanding AOSD
AOSD, originally referring to the systemic onset of juvenile chronic arthritis, can also occur in adults. Once known as subsepsis allergiea, the disease has been termed AOSD since 1987. Its etiology remains unclear, but it is characterized by fever, joint pain, arthritis, rash, neutrophilia, and in severe cases, systemic damage.
Jinnamab’s Clinical Studies
Jinnamab, an anti-interleukin 1-β monoclonal antibody (mAb), is undergoing multiple clinical studies in China. These include trials in acute gouty arthritis, systemic juvenile idiopathic arthritis, and advanced solid tumors when combined with tislelizumab.-Fineline Info & Tech